Florida-based Veritas Bio won approval from the European Patent Application for its delivery technique for RNA-based drugs. The technology enables small pieces of RNA, which can be used to "silence" genetic traits, to reach the liver and treat diseases affecting the organ.
Shares of the Calabasas, CA-based biotech outfit shot up more than 25% to $42 midmorning on Tuesday after its Monday release on the results. The promise of ATX-101 could make Kythera a buyout target, an analyst from Cowen & Co. noted, and recommended buying the company's shares.
Medtronic is opening up a $10.2 million R&D operation in Galway, Ireland, planning to put local minds to work on developing new cardiovascular devices.
Antimicrobial resistance is on the rise in the U.S. and elsewhere, and healthcare providers are running out of drugs in their arsenal to combat some pathogens, leaving patients vulnerable to dangerous infections, according to a new federal report.
The Center for Brains, Minds and Machines, based in Cambridge, MA, is one of three new centers to win funding from the NSF's Science and Technology Centers Integrative Partnerships.
Indiana-headquartered CRO Harlan Laboratories has expanded its specialty research production facility in Southern Europe, offering contract breeding service for sponsors who need animal models for clinical trials.
Theorem Clinical Research has struck a deal with Charles River Laboratories, adding the early-phase-focused CRO's capabilities to its drug development platform.
Eli Lilly has found a new path into the hot rare-disease field. An NIH program has backed the Indianapolis-based drug giant's preclinical-stage research of a potential treatment for a hormone deficiency often caused by a genetic defect.
The Affordable Care Act will help produce big gains in the coming years for device companies that produce blood glucose meters and other home care products, according to a new study.
A well-known anesthetic called ketamine may be the revolutionary medicine that drug developers at Johnson & Johnson and elsewhere are chasing to bring the next generation of depression drugs to patients.